Morning Briefing
Summaries of health policy coverage from major news organizations
AbbVie To Pay $350M In Exchange For United Therapeutics' FDA Fast-Track Voucher
It's a record price paid for a priority review voucher. Such tickets entitle the holder to move a new drug through the Food and Drug Administration's review line faster. In other pharmaceutical news, some doctors voice concern over the FDA's approval of Addyi, the pink pill aimed at increasing women's libido.
A deal struck between drugmakers AbbVie and United Therapeutics Wednesday set a record price for a voucher that can be redeemed for a fast-track review of a new medicine by the Food and Drug Administration. (Hensley, 8/19)
Addyi, a new female libido pill, will hit the market this fall, but the prescription drug was twice rejected by the FDA in the past. For a closer look at the uses and risks, Judy Woodruff speaks to Dr. Adriane Fugh-Berman of the Georgetown University Medical Center and Dr. Mary Jane Minkin of Yale Medical Group. (8/19)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
